154 related articles for article (PubMed ID: 34164689)
1. Skull Base Tumors: Neuropathology and Clinical Implications.
Bi WL; Santagata S
Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
[TBL] [Abstract][Full Text] [Related]
2. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
3. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
4. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
[TBL] [Abstract][Full Text] [Related]
5. Skull Base Tumors.
Forst DA; Jones PS
Continuum (Minneap Minn); 2023 Dec; 29(6):1752-1778. PubMed ID: 38085897
[TBL] [Abstract][Full Text] [Related]
6. Neuropathology of Pituitary Adenomas and Sellar Lesions.
Kobalka PJ; Huntoon K; Becker AP
Neurosurgery; 2021 Apr; 88(5):900-918. PubMed ID: 33476394
[TBL] [Abstract][Full Text] [Related]
7. New developments in the pathology of skull base tumors.
Radner H; Katenkamp D; Reifenberger G; Deckert M; Pietsch T; Wiestler OD
Virchows Arch; 2001 Apr; 438(4):321-35. PubMed ID: 11355165
[TBL] [Abstract][Full Text] [Related]
8. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma.
Mete O; Lopes MB; Asa SL
Am J Surg Pathol; 2013 Nov; 37(11):1694-9. PubMed ID: 23887161
[TBL] [Abstract][Full Text] [Related]
9. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
10. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
11. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
12. A Clinical Rule for Preoperative Prediction of BRAF Mutation Status in Craniopharyngiomas.
Fujio S; Juratli TA; Arita K; Hirano H; Nagano Y; Takajo T; Yoshimoto K; Bihun IV; Kaplan AB; Nayyar N; Fink AL; Bertalan MS; Tummala SS; Curry WT; Jones PS; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurosurgery; 2019 Aug; 85(2):204-210. PubMed ID: 30481321
[TBL] [Abstract][Full Text] [Related]
13. Genomic Alterations in Sporadic Pituitary Tumors.
Bi WL; Larsen AG; Dunn IF
Curr Neurol Neurosci Rep; 2018 Feb; 18(1):4. PubMed ID: 29396598
[TBL] [Abstract][Full Text] [Related]
14. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
15. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
16. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.
Schweizer L; Koelsche C; Sahm F; Piro RM; Capper D; Reuss DE; Pusch S; Habel A; Meyer J; Göck T; Jones DT; Mawrin C; Schittenhelm J; Becker A; Heim S; Simon M; Herold-Mende C; Mechtersheimer G; Paulus W; König R; Wiestler OD; Pfister SM; von Deimling A
Acta Neuropathol; 2013 May; 125(5):651-8. PubMed ID: 23575898
[TBL] [Abstract][Full Text] [Related]
17. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
18. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
19. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
20. [What's new in the management of meningeal solitary fibrous tumor/hemangiopericytoma?].
Lottin M; Escande A; Peyre M; Sevestre H; Maurage CA; Chauffert B; Penel N
Bull Cancer; 2020 Dec; 107(12):1260-1273. PubMed ID: 33160607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
